Advertisement
[adinserter block="11" template="Global Header" check="exceptions" ignore="page-type"]

Cardiology General

Validated Cardiac Outcome Prediction Model for Patients With Fabry Disease

Nov 08, 2022

The most common cause of mortality from Fabry disease is cardiac symptoms, yet risk stratification was insufficient. More evidence-based therapy recommendations may be made possible by identifying ind...

Cardiac Amyloidosis Screening 5 to 15 Years After Bilateral Carpal Tunnel Surgery

Nov 08, 2022

A frequent extracardiac amyloidosis presentation, bilateral carpal tunnel syndrome (CTS) typically develops several years before overt cardiac amyloidosis (CA). According to screening studies on patie...

Long-Term Results After Atrial Switch Operation for Great Arteries Transposition

Nov 07, 2022

There was a need to identify risks for end-stage heart failure outcomes in individuals with d-loop transposition of the great arteries (d-TGA) who have a systemic right ventricle following an atrial s...

LVEF Impact on Clinical Outcomes in Bicuspid Aortic Valve Disease

Nov 07, 2022

Prior research has not been done on the prognostic significance of left ventricular ejection fraction (LVEF) in patients with bicuspid aortic valve (BAV) disease. For a study, researchers sought to id...

Congenital AoV Lesions Repair with AP Vs. Porcine Intestinal Submucosa

Nov 07, 2022

Congenital aortic valve (AoV) repair outcomes are hampered by the gradual failure of leaflet replacement materials currently in use. For a study, researchers contrasted the long-term effects of congen...

Cardiogenic Shock: Standardized & Regionalized Care Network

Nov 03, 2022

Cardiogenic shock (CS) treatment standardized across regional care networks has unclear advantages. The authors examined how patients with CS who presented to hub hospitals versus spoke hospitals with...

Impact of Clonal Hematopoiesis in CS Patients Complicating AMI

Nov 03, 2022

Elderly people frequently have clonal hematopoiesis of indeterminate potential (CHIP) raises their risk for cardiovascular disease as well as hematologic cancers. It was unclear how CHIP may affect th...

Dose-Response to Sac/Val in HFrEF Patients

Nov 03, 2022

Clinical practice frequently falls short of sacubitril/valsartan (Sac/Val) doses that were successful in clinical studies for heart failure with reduced ejection fraction (HFrEF). For a study, researc...

Supraventricular Tachycardia (SVT) Recurrence in Infancy

Nov 01, 2022

There was a lack of information on the likelihood of recurrence in newborns with supraventricular tachycardia (SVT). For a study, researchers set out to identify the prevalence and risk factors for SV...

Diabetes Patients' Cumulative Systolic Blood Pressure Load and Cardiovascular Risk

Nov 01, 2022

Standard blood pressure (BP) measurements do not consider the extent and length of exposure to high BP over time. For a study, researchers sought to determine the relationship between type 2 diabetes ...

Frailty and Sacubitril/Valsartan in Heart Failure Patients

Nov 01, 2022

Frailty is an issue that is becoming more and more prevalent, and patients who are frail are less likely to obtain novel pharmacologic treatments because the risk-benefit profile is seen to be less fa...

Diagnosing Dilated Cardiomyopathy Through Pathogenic Genotyping

Nov 01, 2022

Genotyping permits family screening and affects risk stratification in patients with nonischemic dilated cardiomyopathy (DCM) or isolated left ventricular systolic dysfunction (LVSD), but its results ...

Quantitative Flow Ratio Guided Coronary Intervention vs Angiography in Diabetic Patients

Oct 31, 2022

The therapeutic value of the quantitative flow ratio (QFR), a new angiography-based metric for the functional evaluation of coronary stenoses, has recently been proven in patients receiving the percut...

Femoropopliteal Artery Interventions: Determinants of Drug-coated Balloon Failure

Oct 31, 2022

Femoropopliteal artery disease is routinely treated using drug-coated balloons (DCB). However, patency loss happens in ≥10% of patients within a year of therapy, and the underlying processes are poo...

Reduced blood pressure in malignant left ventricular hypertrophy patients

Oct 28, 2022

A significant risk of heart failure and mortality is linked to left ventricular hypertrophy (LVH) accompanied by increases in cardiac biomarkers suggesting myocardial damage and neurohormonal stress (...

Abbreviated APT After Coronary Stenting in HBR Myocardial Infarction Patients

Oct 28, 2022

It was unknown how long patients with acute coronary syndrome and high bleeding risk (HBR) should continue antiplatelet therapy (APT) following coronary stenting. For a study, researchers sought to ex...

Left Bundle Branch Vs. Biventricular Pacing for CRT

Oct 28, 2022

The fastest-growing conduction system pacing method that can treat intrinsic left bundle branch block (LBBB) is called left bundle branch pacing (LBBP). As a result, it may be the best substitute for ...

Population-Based Recalibration of the FRS and PCEs

Oct 28, 2022

In many current cohorts, the Framingham Risk Score (FRS) and Pooled Cohort Equations (PCEs) overstate the risk. For a study, researchers sought to determine whether risk stratification for statin medi...

Hemodynamic & Clinical Performance of DCD Hearts

Oct 28, 2022

Heart transplantation continues to experience a shortage of donor organs. Heart donors may be more readily available for individuals with advanced heart failure if donation after circulatory death (DC...

Dapagliflozin in Patients With Heart Failure & LVEF

Oct 28, 2022

Heart failure (HF) patients who have recently been hospitalized are at significant risk of dying and being readmitted. For a study, individuals with HF with modestly decreased or retained left ventric...